Financings in Brief: Matritech
This article was originally published in The Gray Sheet
Matritech: Nets approximately $6.6 mil. from private placement of 3 mil. shares of common stock at $2.30 per share. Proceeds will be used "to fund ongoing in vitro diagnostic development, therapeutic research, marketing of the company's NMP-22 bladder cancer test kit, working capital and general corporate expenses"...
You may also be interested in...
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.